FindTrial
Sign In

The efficacy evaluation of tocilizumab to glucocorticoid-resistant patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial

The efficacy evaluation of tocilizumab to glucocorticoid-resistant patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial - Efficacy assessment of tocilizumab to steroid-resistant patients with adult Still's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001457
Enrollment
10
Registered
2008-10-28
Start date
2008-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Still&#39

Interventions

Tocilizumab is to be infused every 2 to 4 weeks at 8 mg/kg of body weight

Sponsors

Division of Rheumatology & Clinical Immunology, Jichi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with steroid-resistant adult Still's disease or systemic juvenile idiopathic arthritis who are 18 years or older are to be enrolled.

Exclusion criteria

Exclusion criteria: 1.pregnant women or women trying to get pregnant 2.patients with dementia 3.patients considered inappropriate judged by attending physicians

Design outcomes

Primary

MeasureTime frame
Amount of glucocorticoid-dose tapered after tocilizumab-administration—

Countries

Japan

Contacts

Public ContactMasahiro Iwamoto

Jichi Medical University Division of Rheumatology & Clinical Immunology

hiro-iwa@jichi.ac.jp0285587358

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026